Name | Value |
---|---|
Revenues | 116.5M |
Cost of Revenue | 70.3M |
Gross Profit | 46.2M |
Operating Expense | 38.8M |
Operating I/L | 14.0M |
Other Income/Expense | -9.9M |
Interest Income | 0.0M |
Pretax | 4.1M |
Income Tax Expense | -1.1M |
Net Income/Loss | 5.3M |
OraSure Technologies, Inc. develops, manufactures, and sells oral fluid diagnostic products and specimen collection devices globally. Its products include COVID-19 rapid tests, HIV and HCV tests, oral fluid collection devices, drug testing systems, genomic products, and microbiome collection products. The company also offers molecular testing collection devices for COVID-19, urine collection devices, and genetic material sample collection kits. OraSure markets its products to various entities including clinical laboratories, hospitals, clinics, public health organizations, government agencies, and commercial and industrial entities.